Related Experiment Video

Updated: May 22, 2026

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform
07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Dyslipidemia and its therapeutic challenges in renal transplantation

L V Riella1, S Gabardi, A Chandraker

  • 1Transplantation Research Center, Renal Division, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA. lriella@rics.bwh.harvard.edu

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|May 15, 2012
PubMed

Insights

Kidney transplant recipients often develop dyslipidemia, a risk factor for heart disease. Aggressive treatment with statins, considering safety and potency, is recommended to reduce cardiovascular mortality risk.

Area of Science:

  • Nephrology
  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease is the primary cause of death in kidney transplant recipients.
  • Dyslipidemia is prevalent post-transplantation and a significant risk factor for coronary heart disease.
  • Extrapolating from general population data, aggressive treatment of posttransplant dyslipidemia is warranted.

Purpose of the Study:

  • To review the etiology and treatment strategies for dyslipidemia in renal transplant recipients.
  • To evaluate the benefits and adverse effects of statin therapy in this population.
  • To discuss recent FDA warnings concerning simvastatin.

Main Methods:

  • Literature review of studies on dyslipidemia in renal transplant recipients.
  • Analysis of potential therapeutic benefits and adverse effects of lipid-lowering agents.
  • Evaluation of safety profiles of different statin classes.

Main Results:

  • Statins are the preferred agents for treating dyslipidemia in this group.
  • Pravastatin, fluvastatin, and pitavastatin are considered safer but may require high-potency statins like atorvastatin for efficacy.
  • Recent FDA warnings regarding simvastatin necessitate careful consideration of its use.

Conclusions:

  • Posttransplant dyslipidemia requires aggressive management to mitigate cardiovascular risk.
  • Statin selection should balance safety and efficacy, considering individual patient needs.
  • Awareness of drug interactions and regulatory warnings is crucial for optimizing therapy.

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant01:25

Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant

In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...